Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs